GlassScriptPhysician profile
Steven K Krueger
NPI 1417061987
$388,489.90
in general payments reported to CMS, 2019-2025
40 companies · $585 in 2025
The $585 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $153K · 2020: $76K · 2021: $62K · 2022: $51K · 2023: $46K · 2024: $580 · 2025: $585.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Food and Beverage: $2,403 · Travel and Lodging: $572 · Consulting Fee: $89.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,362.00 |
| Food and Beverage | $2,402.54 |
| Travel and Lodging | $571.82 |
| Consulting Fee | $89.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $101,673.96 | 2019-2024 | Jardiance, Tradjenta, Synjardy |
| Lilly USA, LLC | $57,912.23 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $41,462.08 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $35,910.32 | 2021-2024 | |
| Amarin Pharma, INC. | $35,038.12 | 2019-2021 | |
| Pfizer INC. | $33,663.88 | 2019-2025 | |
| Amgen INC. | $22,122.62 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $15,426.04 | 2019-2025 | Camzyos |
| Esperion Therapeutics, INC. | $15,134.10 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $14,393.30 | 2019-2025 | Evkeeza |
| Sanofi-Aventis U.S. LLC | $13,933.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $644.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $242.81 | 2021-2025 | Verquvo, Keytruda, Welireg |
| Novo Nordisk INC | $215.44 | 2022-2025 | Wegovy, Rybelsus, Ozempic |
| Impulse Dynamics (USA) INC. | $113.53 | 2023-2025 | Optimizer, Optimizer |
Show all 35 companies
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Krueger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.